Figure 3


(A) Time to first pneumonia event in patients on ICS/LABA vs. LAMA. (B) Time to first pneumonia-related hospitalization event in patients on ICS/LABA vs. LAMA. (C) Time to first outpatient pneumonia event in patients on ICS/LABA vs. LAMA. (D) Time to pneumonia-related death in patients on ICS/LABA vs. LAMA. ICS inhaled corticosteroids, LABA long acting β2-agonists, LAMA long-acting muscarinic antagonists.